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158Objectives: Bicuspid aortic valve is the most common congenital cardiac abnormality, occurring in 1% to 2%
of the population, and often associates with ascending aortic aneurysm. Based on familial studies, bicuspid aor-
tic valve with aneurysm segregates in an autosomal dominant manner with incomplete penetrance. NOTCH1
mutations have been reported in 6 families with prominent valve calcification and dysfunction and low pene-
trance of aneurysm. We sought to determine the contribution of NOTCH1 mutations to the more common
phenotype of highly penetrant aneurysms with low penetrance of bicuspid aortic valve and with rare valve
calcification or dysfunction.
Methods: All exons and splice junctions of NOTCH1 were sequenced in probands from 13 affected families
presenting with bicuspid aortic valve with ascending aortic aneurysm in the absence of valve calcification. In
addition, mutation analysis was performed on a single individual with aneurysm and calcified tricuspid aortic
valve. Sequences were aligned and compared with the reference genomic sequence.
Results: Corroborating previous studies, analysis of the single sporadic patient with calcified aortic valve in the
presence of ascending aortic aneurysm revealed a novel heterozygous missense mutation in NOTCH1 resulting
in a nonsynonymous amino acid substitution (p.T1090S, c.C3269G) of an evolutionarily conserved residue. This
change was not observed in controls. In contrast, we did not identify any pathologic NOTCH1 mutations in the
13 families segregating noncalcified bicuspid aortic valve with highly penetrant aortic aneurysm.
Conclusions: These data suggest that there are phenotypic differences that distinguish families with and without
NOTCH1 mutations, indicating a genotype–phenotype correlation with potential implications for patient diag-
nosis, counseling, and management. (J Thorac Cardiovasc Surg 2013;146:158-65)Supplemental material is available online.
Bicuspid aortic valve (BAV) is the most common congenital
cardiac abnormality1,2 affecting about 1% to 2% of
individuals in the general population. It is characterized
by fusion or incomplete formation of valve commissures
during valvulogenesis.
Patients with BAV have varying degrees of valvular dys-
function, ranging from severe (including stenosis and regur-
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The Journal of Thoracic and Cardiovascular Surgseveral additional cardiovascular phenotypes, including
valve calcification and ascending aortic aneurysm
(AscAA).2-5 However, there is poor correlation between
the extent of valve dysfunction and the incidence or
severity of aortic aneurysm.6-9 Furthermore, patients with
BAV and AscAA have been noted to have dilation of the
pulmonary trunk with histologic findings of cystic medial
necrosis and elastic fiber fragmentation.4,10 Taken
together, these data suggest that the underlying gene
defect(s) causing BAV can directly alter vessel wall
homeostasis. However, recent studies continue to suggest
that eccentric blood flow patterns and/or aortic wall stress,
attributed at least in part to perturbation of valve
morphology and function, contribute to the increased
propensity to aortic dilatation and dissection in patients
with BAV.11,12
It has been shown that BAV, either in the presence or
absence of these additional clinical features, is highly heri-
table,13,14 and appears to segregate in an autosomal
dominant manner with reduced penetrance.4,15,16
However, the molecular basis of the disorder is not yet
well understood.
In 2005, Garg and colleagues17 reported an association
between inactivating mutations in NOTCH1 and autosomal
dominant aortic valve disease with prominent calcification.
Twelve affected individuals in 2 unrelated families wereery c July 2013
Abbreviations and Acronyms
AscAA ¼ ascending aortic aneurysm
BAV ¼ bicuspid aortic valve
TAV ¼ tricuspid aortic valve
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4 of the 9 also affected by aortic aneurysm. Two other
groups have described 4 additional missense NOTCH1
mutations associated with isolated BAV cases, most of
whom had valve calcification and aortic aneurysm.18,19
Table E1 presents the clinical information for individuals
with previously reported NOTCH1 mutations. Thus, it
appears that in some but not all patients with BAV,NOTCH1
mutations are responsible for early valve calcification, sig-
nificant valvular dysfunction, and aortic aneurysm.
Many patients with BAV have a distinct phenotype, in
which the BAV is associated with dilation of the ascending
aorta in the absence of early or aggressive valve calcifica-
tion.3,20 The aneurysms can be observed at the aortic root
or, more commonly, just distal to the sinotubular
junction.8,21 In such families, the disease is inherited in an
autosomal dominant pattern with reduced penetrance.
Family members of affected probands can show AscAA
in the absence of aortic valve abnormality and vice versa,
suggesting that these manifestations share a common
etiology but are not interdependent.4 In fact, in these fami-
lies, AscAA appears to bemore highly penetrant when com-
pared with the penetrance of BAV.
NOTCH1, encoded on 9q34.3, is a member of the type 1
transmembrane receptor protein family. Notch signaling is
an evolutionarily conserved intercellular pathway that plays
a key role in multiple developmental processes by regulat-
ing cell fate decisions.22 Given the reported connection be-
tween calcific aortic valve disease, aortic aneurysm, and
NOTCH1 mutations, we sought to determine the contribu-
tion of NOTCH1 mutations to noncalcific BAV with highly
penetrant AscAA.MATERIALS AND METHODS
Study Subjects
This study was approved by the Institutional Review Board of the Johns
Hopkins University School of Medicine. Individuals were recruited,
enrolled, and evaluated at the Medical Genetics Clinic of the Johns Hop-
kins Hospital as previously described.4 Comprehensive clinical analysis
for the proband and the extended family was completed before genotyping.
History, physical examination, and echocardiograms were obtained for all
individuals who gave informed consent. Figure 1 presents the pedigrees of
families analyzed.
Criteria for Inclusion
Each person was evaluated based on clinical history, examination, and
echocardiography.4 Individuals were considered affected with BAV if
cardiovascular imaging showed complete or partial fusion of any aortic
valve commissure. Individuals were assigned affected status for aneurysmThe Journal of Thoracic and Caif either the aortic root or more distal ascending aorta showed a dimension
with a z score>2 when standardized to age and body size. The z scores were
calculated using the Wave Form Echo Program from Boston Children’s
Hospital for pediatric patients or standard normograms for patients aged
19 years and older.23 In addition, family members with a history of aortic
dissection, rupture, or surgery were coded as affected. The individual
from each family selected for sequencing is indicated by an arrow in
Figure 1.
Criteria for Exclusion
Families demonstrating dysmorphic features or manifestations of a con-
nective tissue disorder were excluded from this study.
NOTCH1 Mutation Analysis
Genomic DNA was isolated from ethylenediaminetetraacetic acid-
treated peripheral blood using the DNeasy Blood Kit according the manu-
facturer’s protocol (Qiagen, Valencia, Calif). Mutation analysis of the
entire NOTCH1 coding sequence was performed using direct DNA
sequencing of polymerase chain reaction-derived amplicons. Amplifica-
tion of all 34 exons and splice junctions of NOTCH1 was achieved using
42 primer pairs derived from previously published sequencing studies
(sequences available upon request)17,18 and the REDExtract-N-Amp
PCR Ready Mix (Sigma-Aldric, St Louis, Mo) per manufacturer’s instruc-
tions. An ABI capillary sequencer (AB, Foster City, Calif) was used for
bidirectional sequencing of each amplicon. The resulting sequences were
analyzed for variants using MacVector software (MacVector, Inc, Cary,
NC) by alignment to the NOTCH1 human reference genome sequence
(NG_007458.1).
If a putative mutation was identified, all available family members in
that pedigree were genotyped. Sequence conservation was assessed by pro-
tein alignment in ClustlW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
The accession numbers of each aligned protein are as follows: Homo sapi-
ens NP_060087, Pan troglodytes XP_001171581, Equus caballus
XP_001498632,Bos taurusDAA24217,Canis familiarisXP_537795,Rat-
tus norvegicus NP_001099191, Mus musculus NP_032740, Gallus gallus
XP_415420, Xenopus laevis NP_001081074, Oncorhynchus mykiss
NP_00112916, Danio rerio NP_571516, and Drosophila melanogaster
NP_476859.RESULTS
Clinical Findings
Pedigrees for the 13 families and the sporadic case in-
cluded in this study are shown in Figure 1. Ten of the fam-
ilies described in our study (families A, D, G, I, J, K, L, M,
Q, and R) were previously reported4; 3 new families (fam-
ilies F, H, and S) were also studied, as well as the individual
with sporadic calcified tricuspid aortic valve (TAV) and
aneurysm of the ascending aorta (pedigree T). Three previ-
ously described families (families N, O, and P) were
excluded due to the lack of sufficient DNA.
All the selected probands had BAV with root or ascend-
ing aortic aneurysm, with the exception of the proband in
family A. This proband (AII:1) presented with BAV, and
was considered affected because she had 2 children with
AscAA and another with BAV.
Detailed clinical descriptions for families A, D, G, I, J, K,
L, M, Q, and R were previously reported.4 These families
include multiple generations of individuals segregating
AscAA, BAV, or the combination, in addition to other leftrdiovascular Surgery c Volume 146, Number 1 159
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FIGURE 1. Pedigrees of 14 families: 13 with bicuspid aortic valve (BAV)/ascending aortic aneurysm (AscAA), and 1 with calcified tricommissural aortic
valve/AscAA. Arrows denote the family member selected for NOTCH1 sequence analysis. AscAA includes both aortic root and ascending aortic dilation.
TGA, Transposition of the great arteries; HLHS, hypoplastic left heart syndrome; COARC, coarctation of the aorta; VSD, ventricular septal defect;
UAV, unicommissural aortic valve; PFO, patent foramen ovale; LCA, left cerebral artery. Adapted with permission from Loscalzo and colleagues.4
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Dventricular outflow track abnormalities. Three additional
pedigrees (F, G, and S) consisted of families with affected
members within a single generation. Two of these (F and
G) were trios with the offspring presenting with BAV and
AscAA.
Proband demographic and clinical data are provided in
Table 1. Of the BAV/AscAA probands included in the fa-
milial cohort (n¼ 13), 10 (77%) were male and the median
agewas 22 years. Two of the probands (15%) were reported
to have unicommissural aortic valves, and 2 (15%) had
BAV with unknown morphology. Of the 9 probands with
known BAV morphology, 8 (62%) had fusion of the right/
left coronary commissure whereas 1 (8%) showed fusion
of the right/noncoronary commissure. Twelve (92%) of
the probands lacked calcification of the aortic valve,160 The Journal of Thoracic and Cardiovascular Surgwhereas the most senior proband at 64 years old (SII:6),
was shown to have moderate asymmetric aortic valve calci-
fication with severe aortic stenosis in addition to mitral
annular calcification. However, his age (64 years) is a poten-
tial confounding variable because aortic valve calcification
is commonly observed in individuals aged 60 years and
older.1,2
Amongst these probands, 1 individual (JII:3) was
reported to have moderate to severe aortic regurgitation
but no aortic valve stenosis. Moderate aortic stenosis and
regurgitation was observed in the proband of family G
(GII:1). Severe aortic stenosis with mild aortic regurgitation
was seen in the proband of family S. Of the remaining
10 probands, 4 had no stenosis or regurgitation, 3 had
mild stenosis and regurgitation, 2 had mild regurgitationery c July 2013
TABLE 1. Proband demographic and clinical data
Proband ID Gender Age (y) Valve status
Cusp
fusion Aortic stenosis
Aortic
regurgitation Calc AscAo dilation (age of surgery [y])
A II:1 F 42 BAV R-L    No AscAA
D III:2 M 26 BAV R-L Mild Mild  AscAo z>3
F II:1 M 25 BAV R-L    Valve-sparing AR replacement (25); coarc
G II:1 M 20 UAV N/A Moderate Moderate  Combined AV/AscAo replacement (15)
H II:1 M 9 BAV R-L Very mild Mild  Valve-sparing AR replacement (9)
I II:2 F 15 BAV R-L  Mild  AR z>2; STJ z>3; AscAo z>3
J II:3 M 22 BAV R-L  Moderate to
severe
 AR z>3; AscAo z>3
K III:5 M 49 BAV Unk Mild   Valve-sparing AR replacement (49)
L IV:3 M 7 BAV R-non    Combined AV/AscAo replacement (5)
M III:4 M 16 BAV R-L    AR z>3; STJ z>3; AscAo z>3; coarc
Q IV:5 F 49 BAV R-L  Mild  Valve-sparing AR replacement (44)
R II:1 M 22 UAV N/A Mild Mild  Valve-sparing AR replacement (15)
S II:6 M 64 BAV Unk Severe Mild Moderate Combined AV/AscAo replacement (64)
T II:4 M 56 TAV   þ AscAo z>3
Calc, Calcification; AscAo, ascending aorta; F, female; BAV, bicuspid aortic valve; R-L, right-left commissural fusion; AscAA, ascending aortic aneurysm; M, male; AR, aortic
root; coarc, coarctation of the aorta, N/A, not applicable; AV, aortic valve; z, z score; STJ, sinotubular junction; Unk, unknown; R-non, right noncommissural fusion; UAV,
unicommisural aortic valve; TAV, tricuspid aortic valve.
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(62%) had surgery to repair an AscAA with a majority
(n ¼ 5) undergoing a valve-sparing procedure.
In contrast, the sporadic individual (TII:4) with an
extensively calcified TAV and a diffuse fusiform AscAA
measuring 4.3 cm distal to the STJ was 56 years old at as-
certainment. His 3 older siblings had normal echocardio-
grams. The patient’s father (TI:1) lived to 81 years of age
and died from pulmonary failure; he was known to have sig-
nificant arthrosclerosis. The patient’s mother (T:I:2) died at
age 87 years. Although therewas a family history of obesity,
there was no known history of aortic aneurysm or BAV.
NOTCH1 Sequencing Results
After sequencing all 34 exons and splice junctions of
NOTCH1 in probands from each of 13 affected families,
all known polymorphic variants were cataloged (Table 2).
Minor allele frequencies were ascertained from the 1000
Genomes Project European ancestry population because
this best represents the demographics of our families.
A single novel intronic variant was identified, exon
16þ20G>A in the proband (SII:6) from family S. This var-
iant, although noncoding, could theoretically have an effect
on splicing; however, it does not have an intuitive effect on
messenger RNA processing or stability. Additionally, this
variant was identified in his unaffected brother (SII:3),
further supporting its neutrality. The proband from family
S (SII:6) was also heterozygous for a nonsynonymous var-
iant in exon 25 p.P1377S (c.C4129T) (Figure 2). This var-
iant was absent in his affected brother (individual SII:5)
with BAV and coarctation of the aorta in the absence of
AscAA and present in his unaffected brother (SII:3)
(Figure 2, B). Protein alignment analysis showed that thisThe Journal of Thoracic and Caamino acid is not highly conserved, because rat and mouse
NOTCH1 show serine at this position whereas humans have
proline (Figure 2, B). This variant was previously observed
in BAV cases and was rejected as pathogenic in those
studies because it was also detected in similar frequencies
in control individuals.18,19 Hence, this variant is also
unlikely to be pathogenic.
A coding variant was also identified in the proband from
family T (TII:4). This individual had AscAA and early and
severe calcification and dysfunction of a TAV. He was het-
erozygous for a threonine to serine (p.T1090S;c.C3269G)
substitution in exon 20 (Figure 2, C). This mutation is
located within an epidermal growth factor-like domain
and involves a residue that is highly conserved through evo-
lution. It was not observed in 180 human control chromo-
somes and was also absent from publicly available
databases, including the 1000 genomes project. No addi-
tional family members were available for segregation
analysis.
No other variants were identified in the probands from the
other pedigrees.
DISCUSSION
The results of this study indicate that NOTCH1mutations
do not contribute significantly to the more common pheno-
type of noncalcific BAV and AscAA. The underlying
genetic cause for families with highly penetrant AscAA
and low penetrance of BAV in the absence of aggressive
valve calcification or dysfunction has yet to be elucidated.
BAV With AscAA
BAV with AscAA is a phenotype that shows autosomal
dominant inheritance with reduced penetrance and variablerdiovascular Surgery c Volume 146, Number 1 161
TABLE 2. Genetic variants within the human NOTCH1 gene in bicuspid aortic valve (BAV)/ascending aortic aneurysm (AscAA) probands
SNP ID
Genomic position
NOTCH1 gene position
cDNA position
AA change
Minor MAF MAF
(NG_007458.1) (NM_017617.3) Allele Probands 1000 gen
rs7028061 g.4849 T>C 50 UTR - 76 T/C A 0.38 0.329
rs4489420 g.26979 T>C Exon 3 c.312T>C p.N104N A 0.54 0.487
rs72775789 g.27550 C>A Exon 4 - 49 C/A T 0.04 0.01
rs2229975 g.31331 G>A Exon 5 c.852G>A p.P284P T 0.15 0.228
rs9411208 g.33042 C>T Exon 8 þ 7 C/T G 0.50 0.513
rs9411254 g.33359 C>T Exon 9 - 43 C/T G 0.35 0.636
rs11145767 g.33525 A>G Exon 9 þ 10 A/G T 0.38 0.636
rs10781498 g.33617 C>T Exon 9 þ 102 C/T G 0.40 0.636
rs11574887 g.33620 C>T Exon 9 þ 105 C/T A 0.08 0.075
rs4880100 g.34560 A>G Exon 10 - 133 A/G T 0.62 0.636
rs4880099 g.34650 T>C Exon 10 - 43 T/C A 0.38 0.387
rs3124603 g.35062 A>G Exon 11 - 9 A/G T 0.64 0.612
rs62579232 g.35591 C>T Exon 12 þ 94 C/T A 0.31 0.168
rs3812609 g.36347 G>A Exon 13 þ 70 G/A T 0.15 0.165
rs2229971 g.37307 T>C Exon 14 c.2265T>C p.N755N A 0.69 0.66
rs3812608 g.37787 G>A Exon 15 þ 21 G/A C 0.58 0.483
Novel g.39655 G>A Exon 16 þ 20 G/A Novel 0.04 No data
rs11574894 g.39709 G>A Exon 16 þ 74 G/A T 0.08 0.056
rs9411206 g.39738 T>C Exon 16 þ 103 T/C A 0.38 0.413
rs3125002 g.39878 T>C Exon 17 - 104 T/C A 0.54 0.466
rs3125001 g.39978 G>A Exon 17 - 4 G/A C 0.67 0.575
rs36119806 g.40146 C>T Exon 17 þ 12 C/T A 0.08 0.109
rs3124598 g.41685 A>G Exon 19 - 31 A/G T 0.27 0.429
rs11145765 g.41959 G>A Exon 19 þ 42 G/A T 0.08 0.097
rs3125000 g.41971 A>G Exon 19 þ 54 A/G T 0.31 0.429
rs35987207 g.41998_41999ins C c.3171þ81_3171þ82insC No data 0.50 No data
rs3812603 g.42331 A>G Exon 20 - 71 A/G T 0.33 0.429
rs3124597 g.42576 A>G Exon 20 þ 21 A/G T 0.38 0.429
rs4880098 g.44335 G>A Exon 24 þ 75 G/A C 0.50 0.549
rs11145764 g.44833 G>A Exon 25 - 73 G/A C 0.52 0.55
rs61751542 g.45020 C>T Exon 25 c.4129C>T p.P1377S A 0.04 0.016
rs13300218 g.45598 C>T Exon 26 - 85 C/T A 0.08 0.1
rs11574903 g.46169 C>T Exon 26 þ 55 C/T A 0.23 0.219
rs10521 g.47532 C>T Exon 27 c.5094C>T p.D1698D G 0.54 0.596
rs12344155 g.48256 T>C Exon 28 - 43 T/C G 0.08 0.1
rs3124594 g.48831 T>C Exon 30 - 43 T/C A 0.42 0.472
rs11574906 g.49126 A>T Exon 30 þ 87 A/T A 0.08 0.098
rs11574908 g.49928 C>T Exon 31 - 12 C/T A 0.10 0.083
rs9632944 g.51932 T>C Exon 33 þ 44 T/C G 0.08 0.098
rs2229974 g.53603 C>T Exon 34 c.6555C>T p.D2185D G 0.40 0.423
SNP ID, Single nucleotide polymorphism identification; cDNA, complementary DNA; AA, amino acid; MAF, minor allele frequency.
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fully illustrated.4,15,16 Thus we maintain high incentive to
identify a molecular marker for disease predisposition.
Mutations in NOTCH1 have been associated with aortic
valve disease in familial as well as sporadic cases.17-19
Garg and colleagues17 compellingly demonstrated the link
between inactivating mutations in NOTCH1 and autosomal
dominant aortic valve disease with pronounced calcification
in 2 unrelated families. Nine individuals had BAV and
amongst these, dilated ascending aorta was noted in four in-
dividuals. One individual with AscAA, TAV, no valve calci-
fication, and normal valve function was negative for the162 The Journal of Thoracic and Cardiovascular Surgfamilial NOTCH1 mutation.17 Four additional missense
mutations were subsequently reported in sporadic BAV
cases.18,19 Each of these cases had a phenotype of
dysfunctional BAV with stenosis/insufficiency and
coexisting AscAA and all but 1 also showed prominent
calcification. Taken together, these patient phenotypes
indicate that valve malformation, calcification, and
dysfunction are the predominant phenotype caused by
altered NOTCH1 signaling (Table E1).
Because the contribution of NOTCH1 mutations to BAV
with AscAA in the absence of valve calcification has not
been established, we chose to approach this question byery c July 2013
FIGURE 2. Characterization of coding variants identified within NOTCH1. A, Schematic of NOTCH1 protein domains with the location of each variant
indicated. B, Variant P1377S in family S is present in proband SII:6 and unaffected sibling (Sib) SII:3, but absent in a control and affected sibling SII:5.
Protein conservation reveals proline at position 1377 is not conserved in rat and mouse. C, Variant T1090S in proband TII:4. This substituted amino
acid is conserved down to fruit fly. EGF, Epidermal growth factor; LIN, LIN-12/Notch repeats; FCS, furin cleavage site; TMD, transmembrane domain;
RAM, RAM domain; ANK, ankyrin repeats; PEST, proline, glutamate, serine, threonine-rich degradation motif; BAV, bicuspid aortic valve; AscAA, ascend-
ing aortic aneurysm.
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penetrance of aortic valve dysmorphology and dysfunction.
The absence of NOTCH1 mutations in our cohort,
although identifying a potentially pathogenicNOTCH1mu-
tation in a sporadic individual with AscAA and prominent
calcification, suggests that there are phenotypic differencesThe Journal of Thoracic and Cathat distinguish families with and without NOTCH1 muta-
tions. We suggest that at least 2 distinct disease mechanisms
exist: a NOTCH1-dependent mechanism that produces
stenotic, insufficient and/or calcified aortic valve with rare
aneurysm, and a NOTCH1-independent mechanism that
produces highly penetrant AscAA in the presence ofrdiovascular Surgery c Volume 146, Number 1 163
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fication of the causative gene for BAV patients is important
not only for understanding the mechanism of disease, but
also from the perspective of managing the disease, espe-
cially given that aortic valve calcification, dysfunction,
and aortic aneurysm show an age-dependent onset.
Screening for NOTCH1Mutations and Follow-up
In general we show that NOTCH1 mutations are exceed-
ingly rare, with now a total of 7 reported to date (Table E1).
Therefore, it would be low yield and cost-ineffective to
genotype all families with BAV and AscAA, in particular
families with decreased penetrance of BAV and highly
penetrant AscAA who have a low incidence of early valve
calcification. When screening family members of patients
with NOTCH1mutations, the presence of BAV, aortic valve
calcification, and/or aortic valve dysfunction suggests these
individuals are affected, and hence require continual care
and monitoring. On the other hand, the absence of BAV
does not exclude the presence of a pathologic NOTCH1
mutation or the predisposition for aneurysm, because data
from our lab and others show variable clinical expression
of NOTCH1 mutations in the context of TAV. More study
is necessary to determine if valve calcification can be
a robust read out for NOTCH1 mutations. It is also notable
that a full phenotypic description of children with NOTCH1
mutations is lacking.
For patients with the more common presentation of non-
calcific BAV with aortic aneurysm, due to the variable
penetrance, variable expression and age-dependent onset
of AscAA, we recommend that family members of affected
individuals be regularly monitored by echocardiogram for
AscAA regardless of their aortic valve morphology. First-
degree as well as more distantly related individuals should
have regular echocardiograms and imaging studies that in-
clude the ascending aorta distal to the sinotubular junction.
Based on our observations and other reported stud-
ies,17-19 we suggest that patient management should differ
between patients with BAV and families with and without
NOTCH1 mutations.
Surgical Management
Individuals with BAV have an increased risk for aortic
aneurysms and dissections. Although aneurysms and dis-
sections can be observed in individuals in the absence of
aortic valve abnormalities, the incidence of such abnormal-
ities in patients with BAV is 8- to 10-fold greater than in
patients with no aortic valve abnormalities.2,3,14,24,25 BAV
with AscAA carries a significant burden of disease with
important surgical implications. We propose that there
may be different etiologies of different subclasses of BAV.
In terms of implications for management, disruption of
NOTCH1 expression primarily affects valve calcification,
morphology, and function, and AscAA generally occurs in164 The Journal of Thoracic and Cardiovascular Surgthe setting of significant hemodynamic perturbations. For
those patients with BAV with unequivocally pathologic
NOTCH1 mutations, there should be significant concern
regarding the long-term durability of the native aortic valve.
Such patients will likely require valve replacement within
their lifetime, and they may benefit from early valve
replacement because this may reduce their risk of secondary
aortic aneurysms.
In contrast, in the more common presentation of high
penetrance of AscAA with low penetrance of BAV (with
minimal calcification or dysfunction), it appears that the
underlying gene defect is altering aortic wall homeostasis
as a primary manifestation. In this scenario, it seems appro-
priate to consider sparing the natural aortic valve. In these
patients, valve repair or replacement alone would not be
predicated to mitigate the risk for aneurysm progression
and/or dissection.
Limitations
The limitations of this study must be recognized. There is
a possibility of incomplete ascertainment of the phenotype.
Whereas BAV is congenital, the onset of both aortic valve
calcification and AscAA are age-dependent, leading to the
possibility of misclassification. Although our proposed cor-
relation between early valve calcification and the presence
of a NOTCH1 mutation is based on (1) the mutation-
negative status of 13 of 13 families without significant valve
calcification, (2) our identification of a NOTCH1 mutation
in the sole individual in our study with early valve calcifica-
tion, and (3) the documentation of aggressive valve calcifi-
cation in a vast majority of patients previously reported to
have NOTCH1 mutations (Table E1), further prospective
work is needed to define the full predictive power of this
apparent phenotype–genotype correlation. Furthermore,
although we provide significant genetic evidence that the
novel missense mutation (T1090S) observed in our case
of AscAA in the presence of calcified aortic valve likely
contributes to the phenotype, we must be cautious when
concluding that this is absolutely the cause of disease in
the absence of functional studies. Further analysis was lim-
ited by the inability to study additional family members.
Another limitation is that we did not analyze the untrans-
lated regions of the NOTCH1 gene or look for duplica-
tions/deletions involving NOTCH1.
In conclusion, BAV with the predisposition for aortic
aneurysm is not a single disorder. Understanding of disease
genes and elucidation phenotype–genotype correlations
will inform patient diagnosis, counseling, and management.
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TABLE E1. Clinical information for individuals with reported disease causing NOTCH1 mutations
Study Mutation ID Gender Age
Valve
morphology
Cusp
fusion
Aortic
stenosis
Aortic
insufficiency Calc
AscAA, surgery (age in y),
other CV abnormalities
Garg et al. R1108X II-1 F TAV N/A þ þ þ Dilated AscAo, AVR (65)
"* II-2 F BAV Unk þ ? þ AVR (76)
" III-3 F Dysmorphic TAV N/A ? ? þ
"* III-5 M BAV Unk Severe ? þ Dilated AscAo, AVR (26)
" III-6 M BAV Unk ? Severe þ AVR (33)
" III-8 F BAV Unk ? Mild Unk
" IV-2 M TAV N/A Mild ? þ
" IV-4 M BAV Unk ? ? Unk VSD, MS, parachute MV
" V-1 M BAV Unk Mild ? þ Dilated AscAo
H1505del II-1 F BAV Unk Severe ? þ AoR, AVR
" III-1 M BAV Unk ? ? Unk MA, HLV, DORV
" III-2 M BAV Unk Severe ? þ AVR
Mohamed et al. T596M M 49 BAV R-L, R-non Mild Mild þ Dilated AscAo [4.7 cm]
P179H M 55 BAV R-L Mild Mild þ Dilated AscAo [5.3 cm]
McKellar et al. A1343V F 41 BAV with Raphe R-L þ ?  AVR, graft replacement
of AscAo [at 4.3 cm]
P1390T M 55 BAV R-non þ ? þ AVR, reduction aortoplasty
[at 4.5 cm]
Current study T1090S TII:4 M 56 TAV N/A   þ Dilated AscAo [4.53 cm],
abnormal diastolic function
ID, Identification; Calc, calcification; AscAA, ascending aortic aneurysm; CV, cardiovascular; F, female; TAV, tricuspid aortic valve; N/A, not applicable; AscAo, ascending aorta;
AVR, aortic valve repair; BAV, bicuspid aortic valve;Unk, unknown;M, male; VSD, ventral septal defect;MS, mitral stenosis;MV, mitral valve; AoR, aortic root replacement;MA,
mitral atresia;HLV; hypoplastic left ventricle;DORV, double outlet right ventricle; R-L, right-left commissural fusion; R-non, right-non commissural fusion. *Carriers assumed to
have NOTCH1 mutations but this was not confirmed by sequencing.
Congenital Heart Disease Kent et al
165.e1 The Journal of Thoracic and Cardiovascular Surgery c July 2013
C
H
D
